Remicade (infliximab), a new
targeted biologic therapy, will
be reimbursed on the PBS for
Australians with acute severe
ulcerative colitis.
The product is a new non-surgical
treatment option when previously
emergency surgery constituted the
main alternative for patients who
failed to respond to prior therapy.
Acute ulcerative colitis is a chronic
inflammatory bowel disease.
The symptoms can be debilitating
and may include abdominal pain,
abnormal bowel movements,
urgency, fever, fatigue and the
presence of blood in stools.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.